Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)Newsfile Corp • 01/12/26
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton To Potentially Recover LossesGlobeNewsWire • 01/12/26
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens BermanGlobeNewsWire • 01/09/26
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)Business Wire • 01/09/26
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 01/08/26
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)Newsfile Corp • 01/07/26
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?Zacks Investment Research • 01/05/26
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable DrugSeeking Alpha • 01/04/26
Corcept Tanks on FDA's CRL to Relacorilant NDA in HypercortisolismZacks Investment Research • 01/02/26
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with HypercortisolismBusiness Wire • 12/31/25
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock DownZacks Investment Research • 11/05/25
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss EstimatesZacks Investment Research • 11/05/25
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate UpdateBusiness Wire • 11/04/25
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/22/25
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor TreatmentBusiness Wire • 10/19/25
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian CancerZacks Investment Research • 10/15/25